Rezolute is trading 10.09% lower at $3.94 in pre-market, with no clearly reported company-specific announcement on October 8, 2026, explaining the decline.
- On October 5, the FDA recommended a pre-BLA meeting after reviewing Phase 3 sunRIZE data. The trial missed its primary and key secondary endpoints, and the FDA did not determine that the drug is approvable.
- The October 5 news is prior context, not a confirmed cause of the morning decline.
- U.S. index futures are lower, with the supplied market moves under 0.5%.